Silence Therapeutics Updates Pipeline with Positive Clinical Data for Divesiran and SLN312
Summary
Silence Therapeutics released an updated corporate presentation detailing positive Phase 1 clinical data for Divesiran in Polycythemia Vera and new positive Phase 1 results for SLN312 in dyslipidemia, alongside key upcoming pipeline milestones.
Key Events
-
Positive Divesiran Phase 1 Data Detailed
The presentation provides further details on the durable efficacy of Divesiran in Polycythemia Vera, with patients remaining phlebotomy-free for nearly a year after the last dose, reinforcing data presented at EHA on June 11, 2026.
-
New Positive SLN312 Phase 1 Results
New Phase 1 data for SLN312 in dyslipidemia, presented at the May 2026 EAS Congress, showed robust and dose-dependent reductions in ANGPTL3, triglycerides, and atherogenic lipoproteins, with Silence regaining global rights to the program.
-
Key Pipeline Milestones Outlined
Upcoming milestones include topline Phase 2 results for Divesiran in Polycythemia Vera in Q3 2026, and anticipated IND filings for SLN365 (HoFH) in 1H 2027 and SLN098 (Obesity) in 2H 2027.
Analysis
This 8-K furnishes an updated corporate presentation detailing recent positive clinical data for two key pipeline assets. The presentation provides further insights into the durable efficacy of Divesiran in Polycythemia Vera, following its Phase 1 study. Additionally, it discloses new positive Phase 1 results for SLN312 in dyslipidemia, highlighting robust ANGPTL3 reductions and a competitive profile, with Silence set to regain global rights to the program. The update also outlines upcoming milestones, including Divesiran's Phase 2 topline results in Q3 2026 and future IND filings for other programs.
At the time of this filing, SLN was trading at $7.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $355.7M. The 52-week trading range was $4.19 to $8.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.